Skip to main content

Ginkgo Bioworks Holdings, Inc.

For the period ended Mar 31, 2026. Filed May 7, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2026 · Filed May 7, 2026

DNA$12.01-2.9%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Operations and Comprehensive Loss

(in thousands, except share data)

Three Months Ended March 31,
20262025
Revenue (1)$19,474$38,230
Costs and operating expenses:
Cost of other revenue3,0984,090
Research and development49,92070,923
General and administrative37,83039,723
Restructuring charges—4,466
Total operating expenses90,848119,202
Loss from operations(71,374)(80,972)
Other income (expense):
Interest income, net3,5966,081
Loss on investments(1,214)(3,693)
Other expense, net(7,147)(4,638)
Total other expense(4,765)(2,250)
Loss from continuing operations before income taxes(76,139)(83,222)
Income tax (benefit) expense(80)88
Net loss from continuing operations$(76,059)$(83,310)
Net loss from discontinued operations, net of tax(6,528)(7,647)
Net loss$(82,587)$(90,957)
Net loss per share:
Basic from continuing operations$(1.28)$(1.54)
Basic from discontinued operations(0.11)(0.14)
Basic$(1.39)$(1.68)
Weighted average common shares outstanding:
Basic59,563,45454,241,619
Comprehensive loss:
Net loss(82,587)(90,957)
Other comprehensive (loss) income:
Foreign currency translation adjustment(579)849
Unrealized gains (loss) on available-for-sale securities(78)107
Total other comprehensive (loss) income(657)956
Comprehensive loss$(83,244)$(90,001)

(1)Includes related party revenue ofzero and$8,098 for the three months ended March 31, 2026 and 2025, respectively.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.